Arcellx, Inc.
ACLX
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic coā¦ read more
Healthcare
Biotechnology
3 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$73.25
Price+0.34%
$0.25
1Y
Price
Market Cap
$4.058b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-1089.9%
EBITDA Margin-1127.1%
Net Profit Margin-1000.3%
Free Cash Flow MarginRevenue
$35.898m
-66.7%
1y CAGR-23.0%
3y CAGR-17.2%
5y CAGREarnings
-$217.903m
-103.0%
1y CAGR-30.8%
3y CAGR-70.7%
5y CAGREPS
-$3.94
-97.0%
1y CAGR-22.5%
3y CAGR-47.0%
5y CAGRBook Value
$440.777m
$655.918m
Assets$215.141m
Liabilities$51.794m
DebtDebt to Assets
7.9%
-0.2x
Debt to EBITDAFree Cash Flow
-$201.175m
-107.6%
1y CAGR+7.9%
3y CAGR-11.4%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company